BONESUPPORT announced the first publication of a U.S. clinical pilot study reporting on surgical technique and outcomes of CERAMENT G in trauma.
The technique used in this pilot study included debridement, Flow-FX 2-CAN delivery of CERAMENT G, with local antibiotic elution and when required, stable fixation. Patients with either fracture-related infections or osteomyelitis were followed for an average of 14.4 months. Across all cases, the authors reported no recurrence of infection, no major complications or amputations and radiographic union.
“This first U.S.‑based publication from a single Level‑1 trauma center evaluating CERAMENT G provides a clear, technique‑driven guidance for surgeons managing challenging cases after trauma. Despite its pilot scale, it underscores the effectiveness of CERAMENT G in intramedullary use, combining infection control with reliable bone healing. It further strengthens our momentum in the U.S. trauma market by highlighting a technique well aligned with American surgical practice,” said Torbjörn Sköld, CEO of BONESUPPORT.
BONESUPPORT announced the first publication of a U.S. clinical pilot study reporting on surgical technique and outcomes of CERAMENT G in trauma.
The technique used in this pilot study included debridement, Flow-FX 2-CAN delivery of CERAMENT G, with local antibiotic elution and when required, stable fixation. Patients with either...
BONESUPPORT announced the first publication of a U.S. clinical pilot study reporting on surgical technique and outcomes of CERAMENT G in trauma.
The technique used in this pilot study included debridement, Flow-FX 2-CAN delivery of CERAMENT G, with local antibiotic elution and when required, stable fixation. Patients with either fracture-related infections or osteomyelitis were followed for an average of 14.4 months. Across all cases, the authors reported no recurrence of infection, no major complications or amputations and radiographic union.
“This first U.S.‑based publication from a single Level‑1 trauma center evaluating CERAMENT G provides a clear, technique‑driven guidance for surgeons managing challenging cases after trauma. Despite its pilot scale, it underscores the effectiveness of CERAMENT G in intramedullary use, combining infection control with reliable bone healing. It further strengthens our momentum in the U.S. trauma market by highlighting a technique well aligned with American surgical practice,” said Torbjörn Sköld, CEO of BONESUPPORT.
Copy to clipboard 
